Mar 2026 (Q1 FY26) — May 7, 2026
Lantheus Q1 FY26 — Strong Start with Key Regulatory Approvals and Reaffirmed FY26 Guidance
Read the full callLantheus (LNTH) earnings
- Jun 2026
- Mar 2026 (Q1 FY26)
- Dec 2025
Lantheus earnings: last reported Thu, 7 May 2026, for the quarter ended Mar 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 388 | +2.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 25.8 | +2.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 75.0 | −4.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$99.92 +0.22% · +$0.22
Performance +79.7% 1Y
1Y: $55.6 on 17 Oct 2025 → $99.92. High $110.94 (30 Jun 2026), low $50.69 (10 Nov 2025).
- Previous close
- $99.7
- 52-week range
- $50.69 – $110.94
- One year
- +76.54%
Overview
- Symbol
- LNTH
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Dec 2025 (Q4 FY25) — Feb 26, 2026
Lantheus Q4 FY25 — Strategic Focus on Radiodiagnostics and Strong Pipeline Progress
Read the full callEvery analysed call
Lantheus earnings calls (LNTH)
Financials
What the filings say
Net profit, year on year: −5% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 379 | 391 | 373 | 378 | 384 | 407 | 377 | 388 |
| Operating profit | 134 | 114 | 102 | 88 | 44 | 77 | 81 | 100 |
| Operating margin | 35.3% | 29.1% | 27.4% | 23.3% | 11.4% | 19.0% | 21.6% | 25.8% |
| Interest | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 176 | -1 | 97 | 105 | 42 | 70 | 156 | 94 |
| Tax rate | 25.6% | −1405.8% | 24.4% | 24.6% | 34.5% | 23.1% | 24.3% | 20.0% |
| Net profit | 131 | -12 | 73 | 79 | 28 | 54 | 118 | 75 |
| EPS ($ per share) | 1.89 | — | 1.06 | 1.15 | 0.41 | — | 1.83 | 1.15 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves | -168 | -136 | -150 | -221 | -193 | 134 | 446 | 680 |
| Total liabilities | 369 | 291 | 356 | 399 | 874 | 835 | 892 | 1,138 |
| Fixed assets | 108 | 116 | 120 | 117 | 122 | 147 | 177 | 164 |
| Total assets | 440 | 406 | 870 | 864 | 1,321 | 1,651 | 1,980 | 2,227 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 61 | 80 | 16 | 54 | 282 | 305 | 545 | 390 |
| Cash from investing | -19 | -22 | -5 | 4 | -277 | 6 | -226 | -627 |
| Cash from financing | -5 | -79 | -22 | -39 | 312 | -13 | -119 | -317 |
| Net cash flow | 37 | -20 | -10 | 18 | 317 | 298 | 199 | -554 |
| Capital expenditure | -20 | -22 | -12 | -12 | -278 | -92 | -52 | -36 |
| Free cash flow | 41 | 58 | 4 | 42 | 3 | 213 | 493 | 354 |
LNTH revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Oncology | — | — | — | — | — | — | 64% | 62% | — |
| PYLARIFY | 69% | 68% | 69% | 66% | 63% | 59% | 64% | 62% | -4.1% |
| Definity | 20% | 22% | 21% | 22% | 21% | 21% | 22% | 23% | +5.2% |
| Cardiology | — | — | — | — | — | — | 22% | 23% | — |
| Neurology | — | — | — | — | — | — | 9% | 10% | — |
| Neuraceq | — | — | — | — | 5% | — | 9% | 10% | — |
| Strategic Partnerships and Other | 4% | 2% | 3% | 3% | 4% | 6% | 4% | 5% | +71.9% |
| License and Royalty Revenues | 1% | 1% | 2% | 1% | 2% | 4% | 2% | 3% | +221.5% |
| SPECT Business | — | — | — | — | — | — | 0% | 0% | — |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- US 95% ↑ 1 pt
- Non Us 5% ↓ 1 pt
As LNTH cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
34 filings between Nov 17, 2025 and Aug 31, 2026.
Open market
decisions to buy or sellNobody bought or sold LNTH on the open market in this window. The filings below are 19 awards and 15 tax withholdings.
Compensation
not trading decisions- 19
- Award — granted as compensation
- 15
- Tax withheld — shares kept back by the company to cover tax
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2026 | Marshall Robert J. Jr. CFO and Treasurer | Tax withheld | 721 | $72.8K |
| Aug 17, 2026 | Brown Kimberly Chief Accounting Officer | Tax withheld | 463 | $46.7K |
| Aug 17, 2026 | Dinkelborg Ludger See Remarks | Tax withheld | 2,536 | $255.9K |
| May 14, 2026 | Ber Gerard Director | Tax withheld | 381 | $36.8K |
| May 14, 2026 | Heino Mary Anne Executive Chair and CEO | Tax withheld | 1,227 | $118.6K |
| May 14, 2026 | Maeusli Heinz Christoph Director | Award | 4,137 | $0 |
| May 14, 2026 | Morrow Phuong Khanh Director | Award | 4,137 | $0 |
| May 14, 2026 | McHugh Julie Director | Award | 4,137 | $0 |
| May 14, 2026 | Thrall James H Director | Award | 4,137 | $0 |
| May 14, 2026 | EASTLAND JULIA MARIE Director | Award | 4,137 | $0 |
| May 14, 2026 | Ber Gerard Director | Award | 4,137 | $0 |
| May 14, 2026 | Baylor-Henry Minnie Director | Award | 4,137 | $0 |
| May 14, 2026 | Pruden Gary J Director | Award | 4,137 | $0 |
| May 14, 2026 | LENO SAM R Director | Award | 4,137 | $0 |
| Apr 17, 2026 | Niedzwiecki Daniel See Remarks | Tax withheld | 1,911 | $160.2K |
| Mar 5, 2026 | Morgan Amanda Michelle Chief Commercial Officer | Tax withheld | 595 | $45.4K |
| Mar 5, 2026 | Brown Kimberly Chief Accounting Officer | Award | 6,158 | $0 |
| Mar 5, 2026 | Brown Kimberly Chief Accounting Officer | Tax withheld | 133 | $10.1K |
| Mar 5, 2026 | Marshall Robert J. Jr. CFO and Treasurer | Award | 38,002 | $0 |
| Mar 5, 2026 | Morgan Amanda Michelle Chief Commercial Officer | Award | 26,208 | $0 |
| Mar 5, 2026 | Dinkelborg Ludger See Remarks | Award | 20,966 | $0 |
| Mar 5, 2026 | Niedzwiecki Daniel See Remarks | Award | 36,692 | $0 |
| Mar 5, 2026 | Niedzwiecki Daniel See Remarks | Tax withheld | 1,283 | $97.9K |
| Mar 5, 2026 | Marshall Robert J. Jr. CFO and Treasurer | Tax withheld | 1,182 | $90.2K |
| Mar 2, 2026 | Niedzwiecki Daniel See Remarks | Tax withheld | 8,259 | $630.2K |
| Mar 2, 2026 | Heino Mary Anne Executive Chair and CEO | Award | 32,105 | $0 |
| Mar 2, 2026 | Heino Mary Anne Executive Chair and CEO | Tax withheld | 41,916 | $3.20M |
| Mar 2, 2026 | Marshall Robert J. Jr. CFO and Treasurer | Award | 8,491 | $0 |
| Mar 2, 2026 | Marshall Robert J. Jr. CFO and Treasurer | Tax withheld | 10,652 | $812.7K |
| Mar 2, 2026 | Morgan Amanda Michelle Chief Commercial Officer | Award | 2,782 | $0 |
| Mar 2, 2026 | Morgan Amanda Michelle Chief Commercial Officer | Tax withheld | 3,336 | $254.5K |
| Mar 2, 2026 | Niedzwiecki Daniel See Remarks | Award | 5,169 | $0 |
| Dec 15, 2025 | Morgan Amanda Michelle Chief Commercial Officer | Tax withheld | 368 | $24.5K |
| Nov 17, 2025 | Heino Mary Anne Executive Chair | Award | 14,285 | $0 |
| Aug 29, 2025 | Marshall Robert J. Jr. CFO and Treasurer | Tax withheld | 727 | $39.9K |
| Aug 20, 2025 | PATEL RAJIV A Insider | Sale | 3,365,000 | $188.94M |
| Aug 20, 2025 | FARALLON PARTNERS L L C/CA 10% owner | Sale | 3,365,000 | $188.94M |
| Aug 19, 2025 | FARALLON PARTNERS L L C/CA 10% owner | Sale | 41,000 | $2.27M |
| Aug 19, 2025 | PATEL RAJIV A Insider | Sale | 41,000 | $2.27M |
| Aug 15, 2025 | Brown Kimberly Chief Accounting Officer | Tax withheld | 463 | $25.1K |
| Aug 15, 2025 | Dinkelborg Ludger See Remarks | Award | 14,765 | $0 |
| Aug 13, 2025 | Blanchfield Paul President | Sale 10b5-1 plan | 3,060 | $163.9K |
| Jul 15, 2025 | Blanchfield Paul President | Tax withheld | 518 | $42.1K |
| Jun 13, 2025 | Niedzwiecki Daniel See Remarks | Sale 10b5-1 plan | 6,000 | $472.4K |
| Jun 9, 2025 | Marshall Robert J. Jr. CFO and Treasurer | Option exercise 10b5-1 plan | 14,773 | $737.6K |
| Jun 9, 2025 | Marshall Robert J. Jr. CFO and Treasurer | Sale 10b5-1 plan | 3,494 | $284.0K |
| Jun 9, 2025 | Marshall Robert J. Jr. CFO and Treasurer | Sale 10b5-1 plan | 9,243 | $762.6K |
| Jun 9, 2025 | Marshall Robert J. Jr. CFO and Treasurer | Sale 10b5-1 plan | 27,036 | $2.25M |
| Jun 9, 2025 | McHugh Julie Director | Sale 10b5-1 plan | 5,192 | $423.8K |
| Jun 5, 2025 | Niedzwiecki Daniel See Remarks | Sale 10b5-1 plan | 6,000 | $477.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Lantheus Holdings, Inc.
Free account. Everything above stays public.
Write why you follow Lantheus Holdings, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading